Dexrazoxane: US – FDA and EMA approved
Dexrazoxane is used to prevent cumulative cardiotoxicity caused by anthracycline use in adult or metastatic breast cancer. It prevents the binding of anthracyclines to the heart thus protecting the heart muscle.
It does not affect the efficacy of anthracycline based chemotherapy.
Interleukin-2 (Recombinant): US -FDA approved
Interleukin-2 (IL-2) is used for treatment of metastatic renal cell carcinoma. It increases the lymphocyte population and promotes the destruction of tumour cells.
IL-2 can be used as monotherapy or in combination with other chemotherapy drugs.